CY1114488T1 - Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv - Google Patents

Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv

Info

Publication number
CY1114488T1
CY1114488T1 CY20131100890T CY131100890T CY1114488T1 CY 1114488 T1 CY1114488 T1 CY 1114488T1 CY 20131100890 T CY20131100890 T CY 20131100890T CY 131100890 T CY131100890 T CY 131100890T CY 1114488 T1 CY1114488 T1 CY 1114488T1
Authority
CY
Cyprus
Prior art keywords
preparation
intermediates
microcyclic
hcv
procedures
Prior art date
Application number
CY20131100890T
Other languages
Greek (el)
English (en)
Inventor
Andras Horvath
Dominic John Ormerod
Dominique Paul Michel Depré
Véronique Cerpentier
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of CY1114488T1 publication Critical patent/CY1114488T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/475Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/12Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CY20131100890T 2008-12-23 2013-10-10 Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv CY1114488T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
EP09801447.5A EP2382198B1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (1)

Publication Number Publication Date
CY1114488T1 true CY1114488T1 (el) 2016-10-05

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100890T CY1114488T1 (el) 2008-12-23 2013-10-10 Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv

Country Status (22)

Country Link
US (2) US8927722B2 (enExample)
EP (1) EP2382198B1 (enExample)
JP (1) JP5687631B2 (enExample)
KR (1) KR101734507B1 (enExample)
CN (1) CN102264715B (enExample)
AR (1) AR074863A1 (enExample)
AU (1) AU2009331530B2 (enExample)
BR (1) BRPI0923393B1 (enExample)
CA (1) CA2745565C (enExample)
CY (1) CY1114488T1 (enExample)
DK (1) DK2382198T3 (enExample)
ES (1) ES2429013T3 (enExample)
HR (1) HRP20130906T1 (enExample)
IL (1) IL213246A (enExample)
MX (1) MX2011006764A (enExample)
PL (1) PL2382198T3 (enExample)
PT (1) PT2382198E (enExample)
RU (1) RU2016120007A (enExample)
SI (1) SI2382198T1 (enExample)
SM (1) SMT201300116B (enExample)
TW (1) TWI461424B (enExample)
WO (1) WO2010072742A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923393B1 (pt) 2008-12-23 2018-06-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. "processos para preparar um inibidor de protease de hcv macrocíclico e intermediários e uso".
KR20140063726A (ko) * 2011-09-22 2014-05-27 얀센 파마슈티칼즈, 인코포레이티드 Hcv의 거대고리 단백질 분해효소 억제제의 제조 방법 및 중간물질
MX347650B (es) 2011-10-28 2017-05-05 Janssen Pharmaceuticals Inc Procedimiento mejorado para preparar un compuesto intermedio del inhibidor de proteasa macrociclico tmc 435.
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
AR091279A1 (es) * 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
ES2656087T3 (es) * 2012-06-08 2018-02-23 Gilead Sciences, Inc. Inhibidores macrocíclicos de virus Flaviviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性(r)−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオン−2−カルボン酸の取得方法
JP4218040B2 (ja) 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 3,5,6−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
SI1713823T1 (sl) 2004-01-30 2010-04-30 Medivir Ab Inhibitorji HCV NS-3 serin proteaze
CN101146794A (zh) 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
JP5171624B2 (ja) * 2005-07-29 2013-03-27 テイボテク・フアーマシユーチカルズ C型肝炎ウイルスの大環状阻害剤
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
HRP20100429T1 (hr) * 2007-02-01 2010-09-30 Tibotec Pharmaceuticals Postupci i intermedijeri za pripravu makrocikličkog inhibitora proteaze za hcv
JP5554570B2 (ja) * 2007-02-08 2014-07-23 ヤンセン・アールアンドデイ・アイルランド Hcv阻害大環状フェニルカルバメート
BRPI0923393B1 (pt) 2008-12-23 2018-06-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. "processos para preparar um inibidor de protease de hcv macrocíclico e intermediários e uso".

Also Published As

Publication number Publication date
SMT201300116B (it) 2013-11-08
JP2012513381A (ja) 2012-06-14
CN102264715A (zh) 2011-11-30
KR20110099048A (ko) 2011-09-05
EP2382198B1 (en) 2013-07-10
BRPI0923393A2 (pt) 2015-07-28
PL2382198T3 (pl) 2013-11-29
AR074863A1 (es) 2011-02-16
BRPI0923393B1 (pt) 2018-06-19
US20110257403A1 (en) 2011-10-20
US8927722B2 (en) 2015-01-06
US20150080577A1 (en) 2015-03-19
KR101734507B1 (ko) 2017-05-11
JP5687631B2 (ja) 2015-03-18
HRP20130906T1 (hr) 2013-10-25
CA2745565A1 (en) 2010-07-01
AU2009331530B2 (en) 2015-04-09
RU2011130895A (ru) 2013-01-27
PT2382198E (pt) 2013-10-01
DK2382198T3 (da) 2013-09-30
IL213246A0 (en) 2011-07-31
WO2010072742A1 (en) 2010-07-01
US9115077B2 (en) 2015-08-25
CN102264715B (zh) 2015-12-02
TW201033205A (en) 2010-09-16
EP2382198A1 (en) 2011-11-02
IL213246A (en) 2017-10-31
ES2429013T3 (es) 2013-11-12
HK1164839A1 (zh) 2012-09-28
SI2382198T1 (sl) 2013-11-29
MX2011006764A (es) 2011-08-03
AU2009331530A1 (en) 2011-06-23
TWI461424B (zh) 2014-11-21
RU2016120007A (ru) 2018-11-13
CA2745565C (en) 2017-03-07

Similar Documents

Publication Publication Date Title
CY1114488T1 (el) Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv
CY2017024I1 (el) Παραγωγα αζετιδινης και κυκλοβουτανιου ως αναστολεις των jak
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
BRPI0920263A2 (pt) composto, uso do composto, composição, e, método
HUE056636T2 (hu) Cisz-1,1,1,4,4,4-hexafluor-2-butén azeotróp-jellegû készítményei
BRPI0812159A2 (pt) inibidores de csf-1r, composições e métodos de uso
CY1118231T1 (el) Συνθεση λιποσωματος
CR11861A (es) Compuestos organicos
CL2009001452S1 (es) Pieza agarre cabezal de cuchillas.
PT2963031T (pt) Pró-fármacos de tetrahidrocanabinol, composições compreendendo pró-fármacos de tetrahidrocanabinol e métodos de utilização dos mesmos
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
BRPI0914343A2 (pt) composição, produto, uso da composição e método
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
CY1122115T1 (el) Παραγωγα ν1-ακυλο-5-φθοροπυριμιδινονης
SMP200900065B (it) Derivati ciclizzati come inibitori di EG-5.
DK3348624T3 (da) Sammensætninger, der omfatter hfc-1234yf
BRPI0924081A2 (pt) DERIVADOS DE 5- AMINO -2-(1-hIDROXI-ETIL)- TETRAHIDROPIRANO.
BR112012003152A2 (pt) composição removedora de oxigênio, artigo,e, uso de composição removedora de oxigênio.
ATE492546T1 (de) 6-phenyl-1h-imidazoä4,5-cü-pyridin-4- carbonitrilderivate als cathepsin-hemmer
BRPI0814748A2 (pt) Compostos de alditóis substituídos, composições e métodos
CR20110246A (es) Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica.
BRPI0905726A2 (pt) Derivado de aminoalcanol, composto, uso do derivado de aminoacanol, método de obtenção de derivados de aminoalcanóis e método de obtenção de aminoalcanóis